MenQuadfi

国: 欧州連合

言語: フィンランド語

ソース: EMA (European Medicines Agency)

有効成分:

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid

から入手可能:

Sanofi Pasteur

ATCコード:

J07AH08

INN（国際名）:

meningococcal group A, C, W-135 and Y conjugate vaccine

治療群:

rokotteet

治療領域:

Meningiitti, meningokokki

適応症:

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.

製品概要:

Revision: 8

認証ステータス:

valtuutettu

承認日:

2020-11-18

情報リーフレット

504 GATEWAY TIME-OUT

製品の特徴

504 GATEWAY TIME-OUT